Portal:AOP/FeaturedPathways
From WikiPathways
(Difference between revisions)
| Line 19: | Line 19: | ||
|width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | |width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | ||
|} | |} | ||
| + | * [[Pathway:WP4018]] | ||
Revision as of 14:29, 30 October 2018
|
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
Image does not exist Protein alkylation leading to liver fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Mus musculus) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
|
Image does not exist Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
Image does not exist Nanomaterial induced apoptosis (Homo sapiens) |
Image does not exist Nanoparticle triggered regulated necrosis (Homo sapiens) |
Image does not exist Nanoparticle triggered autophagic cell death (Homo sapiens) |
|
Image does not exist Overview of nanoparticle effects (Homo sapiens) |
Image does not exist Nanomaterial induced inflammasome activation (Homo sapiens) |
Image does not exist Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
